(2004) 109:II2733
In some plans, providers may consider Semax and Dihexa together because they support brain function through different pathways, one leaning toward focus and stress response and the other toward memory and cell communication
More Peptides 5-Amino-1MQ (10mg) BPC-157 BPC-157, TB-500, GHK-Cu (Glow Blend) 60mg CJC-1295 (no DAC), Ipamorelin 10mg (Blend) GHK-Cu 50mg Copper Peptide Kisspeptin-10 5mg KPV (Ac-KPV-NH2) 5mg MOTS-c NAD+ Retatrutide peptide Selank 10mg Semax TB-500 (Thymosin Beta-4) (43aa) Tesamorelin 5mg Thymosin Alpha-1 Tirzepatide peptide Properties Molecular Formula Bpc-157: CHNO Cu-GHK: CHCuNO Timbetasin: CHNO Molecular Weight Bpc-157: 1419.5 Cu-GHK: 403.92 Timbetasin: 4963 Monoisotopic Mass Bpc-157: 1418.70415882 Cu-GHK: 403.1155 Timbetasin: 4960.4863169 Polar Area Bpc-157: 573 Cu-GHK: 176 Timbetasin: 2250 Complexity Bpc-157: 3040 Cu-GHK: 6 Timbetasin: 12200 XLogP Bpc-157: -9 Timbetasin: -43.5 Heavy Atom Count Bpc-157: 100 Cu-GHK: 25 Timbetasin: 347 Hydrogen Bond Donor Count Bpc-157: 16 Cu-GHK: 6 Timbetasin: 72 Rotatable Bond Count Bpc-157: 39 Cu-GHK: 11 Timbetasin: 180 Hydrogen Bond Acceptor Count Bpc-157: 24 Cu-GHK: 7 Timbetasin: 88 Identifiers CID Bpc-157: 9941957 Cu-GHK: 378611 Timbetasin: 16132341 InChI Bpc-157: InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1 Cu-GHK: InChI=1S/C14H24N6O4.Cu/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)
I have been bombarded this past year with questions about peptides
Evidence Boundary Common current format, but FDA noted no published human pharmacokinetic study has formally characterized subcutaneous AOD-9604
